Skipping Cabozantinib Doses Instead of Reducing Them
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether skipping a dose of cabozantinib instead of lowering the dose can help manage side effects while still controlling your kidney cancer. It is for people already taking cabozantinib who might need a break but want to stay on treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced kidney cancer confirmed by biopsy
- You have been taking cabozantinib (20 or 40 mg daily) for at least 4 weeks, with or without nivolumab
- You are not taking medicines that interact with cabozantinib (like certain antifungal, antibiotic, or seizure drugs)
- Your stomach and intestines are working normally (no inflammatory bowel disease or major related surgery)
- You can take the medicine with a regular breakfast
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if people with advanced kidney cancer can safely stop all treatment if a special scan (PET/CT) shows their cancer has shrunk or disappeared. It's for those who have already been on a first-line immunotherapy plus targeted therapy for at least 12 months.
This study looks at whether closer monitoring of cabozantinib levels in the blood can help doctors manage side effects better. It's for people with advanced kidney cancer who are already planning to take cabozantinib.
This Phase 2 study tests a “next-step” cabozantinib strategy for advanced kidney cancer (RCC) after your cancer previously responded to cabozantinib and then progressed. It aims to see if re-using cabozantinib in a planned sequence can control the cancer again with manageable side effects.
This study tests the drug cabozantinib in people with kidney cancer who are also on dialysis. It aims to see if the drug is safe and works for this group.
This Phase 2 study tests a different dosing schedule of cabozantinib (a cancer medicine) for metastatic kidney cancer and certain neuroendocrine tumors. It aims to see if the timing and schedule can work well for people with advanced disease.
This trial is testing a combination of two drugs, cabozantinib and nivolumab, in people aged 70 or older who have advanced kidney cancer that hasn't been treated yet. The goal is to see if this combination works well and is safe for older patients.
Hear when a new Renal Cell Carcinoma (RCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.